CECaroline A. Evans

Caroline A. Evans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Caroline A. Evans has a total of 207 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Uncovering an alternate pathway of antibiotic resistance in spore-forming bacteria

    by Yogitha N. Srikhanta, Clara E. Bate, Desirel Ng, Sarah A. Revitt-Mills, Georgia-Rose Gilmore, Galain C. Williams, Sophie L. Day, Stéphane Mesnage, Kamila Kochan, Shailab Shrestha, et al.

    Spore-forming bacteria produce two distinct cell types: vegetative cells and resilient spores. While antibiotic resistance is typically associated with vegetative cells, spores play a critical role in disseminating resistance genes due to their durability and transmissibility. We previously demonstrated that cephamycin antibiotics target the conserved spore-specific protein SpoVD, significantly reducing spore formation in pathogens including Clostridioides difficile . Here, we show that when C. difficile acquires CdmecA , a homologue of Staphylococcus aureus mecA , one of the most globally burdensome resistance genes, the anti-sporulation effect of cephamycins is bypassed. Cd MecA functionally replaces Cd SpoVD, restoring sporulation and producing phenotypically distinct spores. We further show that mecA is prevalent across C. difficile strains and other pathogenic, gut, and environmental spore-formers. Since SpoVD is conserved, MecA may broadly co-opt sporulation; we confirm this in Clostridium perfringens . This work reveals an unusual resistance mechanism with unexpected physiological consequences, reshaping our understanding of antibiotic resistance within the context of sporulation and microbial adaptation.


  • Open Access

    Rhizobial enzyme reveals pH-driven catalytic switching and ʟ-amino acid incorporation by ʟ,ᴅ-transpeptidases

    by Brooks J. Rady, Raj Bahadur, Caroline A. Evans, Stéphane Mesnage

    Nearly all bacteria are surrounded by a mesh-like macromolecule called peptidoglycan that gives them their shape and helps them resist turgor pressure. To grow and maintain their peptidoglycan, bacteria produce a wide range of enzymes, including the relatively understudied ʟ,ᴅ-transpeptidase (LDT) family. LDTs can catalyse several different reactions and vary widely in copy number: some bacteria have none, whilst others have more than twenty. To better understand why some bacteria have so many LDTs, we examined 18 putative ones from Rhizobium johnstonii , a nitrogen-fixing, symbiotic bacterium. Heterologous expression revealed several highly active enzymes, one of which, Ldt Rj8 , we further characterized in detail. In vitro assays showed that Ldt Rj8 was capable of ʟ,ᴅ-transpeptidation, carboxypeptidation, substitution, and endopeptidation, but that its preferred activity differed at different pHs. Ldt Rj8 particularly excelled at ʟ,ᴅ-substitution, utilizing all of the tested ᴅ-amino acids, and, surprisingly, most of the ʟ-amino acids as well. Ldt Rj8 ’s pH-modulated activity could help R. johnstonii respond to acidic conditions encountered throughout the rhizobium-legume symbiosis, and its ʟ-amino acid substitution activity, which we show to be a more general property of LDTs, may regulate ʟ,ᴅ-transpeptidation and explain the existence of isomeric muropeptides often reported in the literature.

  • Open Access

    The deacetylase NagA mediates the remodeling and recycling of peptidoglycan-derived amino sugars in mycobacteria

    by Collette S. Guy, Charlotte Cooper, Magdalena Karlikowska, James Harrison, Albel Singh, Luis Steven Servín-González, Caroline A. Evans, Saskia E. Bakker, Andrew Bottrill, Apoorva Bhatt, et al.


  • Open Access

    A software tool and strategy for peptidoglycomics, the high-resolution analysis of bacterial peptidoglycans via LC-MS/MS

    by Marcel G. Alamán-Zárate, Brooks J. Rady, Raphael Ledermann, Neil Shephard, Caroline A. Evans, Mark J. Dickman, Robert D. Turner, Aline Rifflet, Ankur V. Patel, Ivo Gomperts Boneca, et al.

    Peptidoglycan is an essential component of the bacterial cell envelope—a mesh-like macromolecule that protects the bacterium from osmotic stress and its internal turgor pressure. The composition and architecture of peptidoglycan is heterogeneous and changes as bacteria grow, divide, and respond to their environment. Though peptidoglycan has long been studied via LC-MS/MS, the analysis of this data remains challenging as peptidoglycan’s unusual composition and branching can’t be handled by proteomics software. Here we describe user-friendly open-source tools and a web interface for building peptidoglycan databases, performing MS searches, and predicting the MS/MS fragmentation of muropeptides. We then use Rhizobium leguminosarum to describe a step-by-step strategy for the high-resolution analysis of peptidoglycan. The unprecedented detail of R. leguminosarum’s peptidoglycan composition (>250 muropeptides) reveals even the subtlest remodelling between growth conditions. These new and easier to use tools enable more systematic analyses of peptidoglycan dynamics.


  • Open Access

    Mass spectrometry-based mRNA sequence mapping via complementary RNase digests and bespoke visualisation tools

    by Emma N. Welbourne, Royce J. Copley, Gareth R. Owen, Caroline A. Evans, Kesler Isoko, Ken Cook, Joan Cordiner, Zoltán Kis, Peyman Z. Moghadam, Mark J. Dickman

    Bespoke visualization tools were developed to enhance the analysis of complementary partial RNase digests via LC-MS. These tools enable efficient identity testing of mRNA through comprehensive sequence mapping.


  • Open Access

    The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells

    by Marieke Rosier, Anja Krstulović, Hyejeong Rosemary Kim, Nihardeep Kaur, Erhumuoghene Mary Enakireru, Deebie Symmes, Katalin Dobra, Ruihuan Chen, Caroline A. Evans, Annica K. B. Gad

    Background: The epithelial-to-mesenchymal transition (EMT) is a common feature in early cancer invasion. Increased vimentin is a canonical marker of the EMT; however, the role of vimentin in EMT remains unknown. Methods: To clarify this, we induced EMT in lung cancer cells with TGF-β1, followed by treatment with the vimentin-targeting drug ALD-R491, live-cell imaging, and quantitative proteomics. Results: We identified 838 proteins in the intermediate filament fraction of cells. TGF-β1 treatment increased the proportion of vimentin in this fraction and the levels of 24 proteins. Variants of fibronectin showed the most pronounced increase (137-fold), followed by regulators of the cytoskeleton, cell motility, and division, such as the mRNA-splicing protein SON. TGF-β1 increased cell spreading and cell migration speed, and changed a positive correlation between cell migration speed and persistence to negative. ALD-R491 reversed these mesenchymal phenotypes to epithelial and the binding of RNA-binding proteins, including SON. Conclusions: These findings present many new interactors of intermediate filaments, describe how EMT and vimentin filament dynamics influence the intermediate filament interactome, and present ALD-R491 as a possible EMT-inhibitor. The observations support the hypothesis that the dynamic turnover of vimentin filaments and their interacting proteins govern mesenchymal cell migration, EMT, cell invasion, and cancer metastasis.


  • Open Access

    The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells

    by Marieke Rosier, Anja Krstulović, Hyejeong Rosemary Kim, Nihardeep Kaur, Erhumuoghene Mary Enakireru, Deebie Symmes, Katalin Dobra, Ruihuan Chen, Caroline A. Evans, Annica Gad

    The Epithelial-to-mesenchymal transition (EMT) is a common feature in early cancer invasion. Increased vimentin is a canonical marker of the EMT, however, the role of vimentin in EMT remains unknown. To clarify this, we induced EMT in lung cancer cells with TGF-β1, followed by treatment with the vimentin-targeting drug ALD-R491, live-cell imaging and quantitative proteomics. We identified 838 proteins in the intermediate filament fraction of cells. TGF-β1-treatment increased the proportion of vimentin in this fraction, and the levels of 24 proteins. Variants of fibronectin showed the most pronounced, 137-fold increase, followed by regulators of the cytoskeleton, cell motility and division, such as the mRNA-splicing protein SON. TGF-β1 increased cell spreading, cell migration speed and changed a positive correlation between cell migration speed and persistence to negative. ALD-R491 reversed these mesenchymal phenotypes to epithelial and the binding of RNA-binding proteins, including SON. These findings present ALD-R491 as a possible EMT-inhibitor and describe how EMT and vimentin dynamics influence the interactome of intermediate filaments. The observations support the hypothesis that the dynamic turnover of vimentin filaments and their interacting proteins govern mesenchymal cell migration, EMT, cell invasion and cancer metastasis.


  • Open Access

    Glycoprofile Comparison of the SARS-CoV-2 Spike Proteins Expressed in CHO and HEK Cell Lines

    by Helen L. Wright, Caroline Evans, Philip J. Jackson, David C. James, Kang Lan Tee, Tuck Seng Wong, Mark J. Dickman, Jagroop Pandhal

    Coronavirus SARS-CoV-2 spike protein remains a key focus of research due to a continued need for diagnostic and therapeutic tools to monitor and respond to new variants. Glycosylation of the spike protein is critical for the protein’s functions in viral attachment and host cell entry. For scalable and cost-effective production of the spike protein, expression system-driven divergence in glycosylation patterns on recombinant spike proteins needs to be fully understood. This study assessed the N-glycosylation profiles of a full-length trimeric spike protein expressed in either Human Embryonic Kidney (HEK Expi293F) or Chinese Hamster Ovary (CHO-S) cells. Glycopeptide analysis was performed using a tandem mass spectrometry workflow and BioPharma $${\hbox {Finder}}^{\textrm{TM}}$$ Finder TM incorporating HEK and CHO glycan databases for protein characterisation. The results outline important differences in the variety and types of N-glycan generated by the two cell lines across the 22 known N-glycosylation sites of the spike protein. A notable increase in terminal sialylation, as well as the presence of the potentially immunogenic N-glycolylneuraminic acid at a functionally key N-glycosylation site, was observed in the CHO-S derived spike protein. With the potential for the relatively vast and more complex CHO glycan repertoire (182 glycans relative to 39 human glycans) to produce functional implications with CHO-S expressed spike protein, this study adds valuable knowledge to aid Quality by Design approaches and enable Multi Attribute Monitoring of specific N-glycosylation sites for proteoform analyses. This can further inform antigen development with future variants in order to devise updated diagnostic tests and therapeutic vaccine designs.


  • Open Access

    Clostridioides difficile canonical L,D-transpeptidases catalyze a novel type of peptidoglycan cross-links and are not required for beta-lactam resistance

    by Nicola F. Galley, Darren Greetham, Marcel G. Alamán-Zárate, Mike P. Williamson, Caroline A. Evans, William D. Spittal, Jessica E. Buddle, Jane Freeman, Georgina L. Davis, Mark J. Dickman, et al.